Literature DB >> 30608349

CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture.

Carol L Shields1, Lauren A Dalvin, David Ancona-Lezama, Michael D Yu, Maura Di Nicola, Basil K Williams, J Antonio Lucio-Alvarez, Su Mae Ang, Sean Maloney, R Joel Welch, Jerry A Shields.   

Abstract

PURPOSE: To use multimodal imaging for identification of risk factors for choroidal nevus transformation into melanoma.
METHODS: Retrospective chart review of 3806 consecutive choroidal nevi with imaging and 2355 choroidal nevi with additional follow up to identify factors predictive of transformation of choroidal nevus into melanoma.
RESULTS: The median patient age was 62.5 years and Caucasian race in 3167 (95%). The choroidal nevus demonstrated median basal diameter of 4.0 mm and thickness of 1.4 mm. Imaging included optical coherence tomography (OCT) showing subretinal fluid (SRF) in 312 (9%), ultrasonography (US) with acoustic hollowness in 309 (9%), and hyper-autofluorescence (AF) in 100 (3%). Of those 2355 choroidal nevi with follow up, Kaplan-Meier estimates of nevus transformation into melanoma at 1, 5, and 10 years were 1.2%, 5.8%, and 13.9%, respectively. Multivariate analysis, using multimodal imaging for detection of factors predictive of nevus transformation into melanoma, included thickness >2 mm on US (hazard ratio (HR) 3.80, p < 0.0001), SRF on OCT as cap over nevus (HR 3.00, p < 0.0001) or SRF ≤3 mm from nevus margin (HR 3.56, p = 0.0003), symptomatic vision loss ≤20/50 on Snellen visual acuity (VA) (HR 2.28, p = 0.005), orange pigment (lipofuscin) hyperautofluorescence on AF (HR 3.07, p = 0.0004), acoustic hollowness on US (HR 2.10, p = 0.0020), and tumor diameter >5 mm on photography (HR 1.84, p = 0.0275). These factors can be recalled by the mnemonic "To Find Small Ocular Melanoma Doing IMaging" (TFSOM-DIM) representing Thickness >2 mm (US), Fluid subretinal (OCT), Symptoms vision loss (VA), Orange pigment (AF), Melanoma hollow (US), and DIaMeter >5mm (photography). The mean 5-year estimates of nevus growth into melanoma were 1% (HR 0.8) for those with 0 risk factor, 11% (HR 3.09) with 1 factor, 22% (HR 10.6) with 2 factors, 34% (HR 15.1) with 3 factors, 51% (HR 15.2) with 4 factors, 55% (HR 26.4) with 5 risk factors, and not-estimable with all 6 risk factors.
CONCLUSION: In this analysis, multimodal imaging was capable of detecting risk factors for nevus transformation into melanoma, including thickness >2 mm (US), fluid subretinal (OCT), symptoms vision loss (Snellen acuity), orange pigment (AF), melanoma hollowness (US), and diameter >5 mm (photography). Increasing number of risk factors imparts greater risk for nevus transformation into melanoma, including thickness >2 mm (US), fluid subretinal (OCT), symptoms vision loss (Snellen acuity), orange pigment (AF), melanoma hollowness (US), and diameter >5 mm (photography). Increasing number of risk factors imparts greater risk for transformation.

Entities:  

Year:  2019        PMID: 30608349     DOI: 10.1097/IAE.0000000000002440

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

Review 1.  Choroidal biopsies; a review and optimised approach.

Authors:  R N Hussain; B Damato; H Heimann
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

Review 2.  Imaging of Uveal Melanoma-Current Standard and Methods in Development.

Authors:  Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

3.  Atypical choroidal nevus in a subject with a germline PALB2 pathogenic variant.

Authors:  Timothy W Grosel; Matthew Karl; Robert T Pilarski; Frederick H Davidorf; Mohamed H Abdel-Rahman; Colleen M Cebulla
Journal:  Fam Cancer       Date:  2021-01-06       Impact factor: 2.375

4.  SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN SMALL CHOROIDAL MELANOMAS AND CHOROIDAL NEVI.

Authors:  Eugenia Custo Greig; Nora V Laver; Luisa S M Mendonca; Emily S Levine; Caroline R Baumal; Nadia K Waheed; Jay S Duker
Journal:  Retina       Date:  2021-06-01       Impact factor: 4.256

5.  Distinguishing Choroidal Nevi from Melanomas Using the MOLES Algorithm: Evaluation in an Ocular Nevus Clinic.

Authors:  Lamis Al Harby; Mandeep S Sagoo; Roderick O'Day; Gordon Hay; Amit K Arora; Pearse A Keane; Victoria M-L Cohen; Bertil Damato
Journal:  Ocul Oncol Pathol       Date:  2021-03-15

6.  The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?

Authors:  Kelsey A Roelofs; Roderick O'Day; Lamis Al Harby; Amit K Arora; Victoria M L Cohen; Mandeep S Sagoo; Bertil Damato
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

7.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

8.  White Paper on Ophthalmic Imaging for Choroidal Nevus Identification and Transformation into Melanoma.

Authors:  Carol L Shields; Sara E Lally; Lauren A Dalvin; Mandeep S Sagoo; Marco Pellegrini; Swathi Kaliki; Ahmet Kaan Gündüz; Minoru Furuta; Prithvi Mruthyunjaya; Adrian T Fung; Jay S Duker; Sara M Selig; Antonio Yaghy; Sandor R Ferenczy; Malvina B Eydelman; Mark S Blumenkranz
Journal:  Transl Vis Sci Technol       Date:  2021-02-05       Impact factor: 3.283

Review 9.  Application of Multimodal and Molecular Imaging Techniques in the Detection of Choroidal Melanomas.

Authors:  Xuying Li; Lixiang Wang; Li Zhang; Fei Tang; Xin Wei
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

10.  Malignant transformation of choroidal nevus according to race in 3334 consecutive patients.

Authors:  Charlotte L Marous; Carol L Shields; Michael D Yu; Lauren A Dalvin; David Ancona-Lezama; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.